Occam’s UK Biotech Practice Accelerates with Placement of CSO at Nucleome
Occam’s traction in the UK biotech market continues to grow with the placement of Steve Harrison, an accomplished global entrepreneurial drug hunter, as CSO of Nucleome Therapeutics, an Oxford spin out and M Ventures/J&J Innovation/Pfizer Ventures/OSE/British Patient Capital investment exploring the dark genome for therapeutic opportunities.
Harrison has three decades of experience in the biotechnology sector, with leadership experience at product-driven research organizations at all stages, from target identification to new drug registration and clinical development in multiple therapeutic areas, including immunotherapeutics, oncology, rare diseases, and pain management.
Prior to Nucleome, Harrison held executive leadership positions at several biotechnology companies in the San Francisco Bay Area, most recently as Chief Scientific Officer of Engine Biosciences. Previous roles include Chief Scientific Officer and Senior Vice President at Relypsa (divested to Galencia for $1.53 billion in 2016).
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.